The FDA approved a supplement to new drug application NDA207924 for baricitinib on 25 September 2026. The applicant is Eli Lilly and Company.
The database entry records the supplement and nothing more. A supplement to an approved application can be a new indication, a new formulation or strength, a labelling change or a manufacturing change - and the record does not say which. Until the approval letter or the revised label is available, the only accurate statement is that something about this application changed.
The reason to note it at all is the class. Janus kinase inhibitors carry boxed warnings for serious infection, mortality, malignancy, major adverse cardiovascular events and thrombosis, arising from the ORAL Surveillance comparison of tofacitinib against tumour necrosis factor inhibitors. Any change to a JAK inhibitor's label is worth checking against those warnings rather than assumed benign. Baricitinib is available in India, and the CDSCO position is unchanged by a US filing.
- The record does not state whether this is a new indication, a formulation change or a labelling change.
- Check the revised label against the class boxed warnings before assuming nothing relevant changed.
- Janus kinase inhibitor warnings cover serious infection, malignancy, cardiovascular events and thrombosis.
- Screen for tuberculosis and viral hepatitis before starting any JAK inhibitor, which matters more in Indian practice.
- A US supplement carries no CDSCO implication; Indian labelling is unchanged.
Why it matters
Label changes to a class carrying boxed cardiovascular and malignancy warnings are the ones worth reading rather than filing.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for clinical pharmacology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free